The company states: “The reduction in net loss from the prior year quarter was primarily related to narsoplimab drug substance manufacturing expenses incurred in the prior year quarter. As previously disclosed, we are in discussions regarding potential asset acquisition and/or licensing agreements in connection with certain of our clinical assets. The most advanced of these discussions relates to an agreement with a potential multi-billion total transaction value exclusive of royalties.” “During the second quarter, we significantly improved our balance sheet, reducing our near-term debt by more than $100 million and adding new capital from a long-horizon investor through an equity financing with Polar Asset Management,” said Gregory A. Demopulos, M.D., Omeros (OMER)’ Chairman and Chief Executive Officer. “Working closely with FDA, we continue preparing for the anticipated approval and subsequent launch of narsoplimab in TA-TMA, an indication with an increasingly large and recognized unmet need for which there is no approved treatment. NIDA has committed to continue funding our PDE7 inhibitor program OMS527, which is being developed to become the first therapeutic for cocaine use disorder and potentially for addictive and compulsive disorders broadly. Our OncotoX-AML program remains on track to enter the clinic in the next 18-24 months and all data generated with the lead compound look promising, showing marked improvement over the current AML standard of care. Currently paused to prioritize narsoplimab, our lead MASP-3 inhibitor zaltenibart and our long-acting MASP-2 inhibitor OMS1029 stand ready to initiate Phase 3 and Phase 2 clinical trials, respectively. With substantial industry interest across our assets, partnering discussions continue advancing, and we see a number of potential value-driving milestones lining up nicely throughout the remainder of 2025 and into 2026.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMER:
- H.C. Wainwright says study could be tailwind to uptake of Omeros’ narsoplimab
- Potential Market Surge for Omeros Driven by Narsoplimab’s Edge Over Eculizumab
- Omeros Enters Securities Purchase Agreement with Polar
- Omeros to sell 5.366M shares at $4.10 in registered direct offering
- Omeros submission adds another 2026 catalyst, says H.C. Wainwright